Wang Xiaobin, Liu Jia, Xi Hong, Cai Liping
Department of Gynaecology, Liaoning Cancer Hospital, 110042, Shenyang, China,
Tumour Biol. 2014 Jul;35(7):6893-900. doi: 10.1007/s13277-014-1915-z. Epub 2014 Apr 16.
Gains of 3q26 chromosome region, where the human telomerase RNA gene (hTERC) is located, have been previously documented in cervical carcinomas. However, published data on this subject are inconclusive. Therefore, we performed a meta-analysis to evaluate the diagnostic value of hTERC in high-grade cervical lesions and invasive cancer. We searched all the eligible studies through PubMed, EMBASE, and the Cochrane Library database without language limitation. Studies were assessed for quality using quality assessment of diagnostic accuracy studies (QUADAS). Positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were pooled separately and compared with overall accuracy measures of diagnostic odds ratio (DOR) and symmetric summary receiver operating characteristic (SROC). The PLR and NLR and their 95 % confidence interval (CI) were calculated using a fixed effects model according to the Mantel-Haensed method and random effects model based on the work of Der Simonian and laird, respectively. A total of 12 studies were included for the analysis. The pooled sensitivity was 0.81 (95 % CI, 0.80-0.82). The pooled specificity was 0.83 (95 % CI, 0.82-0.84). The DOR estimate was performed, and the result was 17.37. Our meta-analysis showed that the detection of genomic amplification of hTERC is a noninvasive and effective approach for high-grade cervical lesions and invasive cancer.
人类端粒酶RNA基因(hTERC)所在的3q26染色体区域增益此前已在宫颈癌中得到记录。然而,关于这一主题的已发表数据尚无定论。因此,我们进行了一项荟萃分析,以评估hTERC在高级别宫颈病变和浸润性癌中的诊断价值。我们通过PubMed、EMBASE和Cochrane图书馆数据库检索了所有符合条件的研究,无语言限制。使用诊断准确性研究的质量评估(QUADAS)对研究质量进行评估。分别汇总阳性似然比(PLR)和阴性似然比(NLR),并与诊断比值比(DOR)和对称汇总接受者操作特征(SROC)的总体准确性指标进行比较。PLR和NLR及其95%置信区间(CI)分别根据Mantel-Haensed方法的固定效应模型和基于Der Simonian和Laird工作的随机效应模型计算。总共纳入12项研究进行分析。汇总敏感性为0.81(95%CI,0.80-0.82)。汇总特异性为0.83(95%CI,0.82-0.84)。进行了DOR估计,结果为17.37。我们的荟萃分析表明,检测hTERC的基因组扩增是一种用于高级别宫颈病变和浸润性癌的非侵入性有效方法。